Publications

Targeting DTX2/UFD1-mediated FTO degradation to regulate antitumor immunity.

Cui YH, Wei J, Fan H, Li W, Zhao L, Wilkinson E, Peterson J, Xie L, Zou Z, Yang S, Applebaum MA, Kline J, Chen J, He C, He YY

Targeting DTX2/UFD1-mediated FTO degradation to regulate antitumor immunity. Proc Natl Acad Sci U S A. 2024 Dec 17; 121(51):e2407910121.

PMID: 39661064

Artificial intelligence-based morphologic classification and molecular characterization of neuroblastic tumors from digital histopathology.

Ramesh S, Dyer E, Pomaville M, Doytcheva K, Dolezal J, Kochanny S, Terhaar R, Mehrhoff CJ, Patel K, Brewer J, Kusswurm B, Naranjo A, Shimada H, Cipriani NA, Husain AN, Pytel P, Sokol EA, Cohn SL, George RE, Pearson AT, Applebaum MA

Artificial intelligence-based morphologic classification and molecular characterization of neuroblastic tumors from digital histopathology. NPJ Precis Oncol. 2024 Nov 08; 8(1):255.

PMID: 39511421

Characterizing Relationships between T-cell Inflammation and Outcomes in Patients with High-Risk Neuroblastoma According to Mesenchymal and Adrenergic Signatures.

Kaufman ME, Vayani OR, Moore K, Chlenski A, Wu T, Lee SM, Desai AV, He C, Cohn SL, Applebaum MA

Characterizing Relationships between T-cell Inflammation and Outcomes in Patients with High-Risk Neuroblastoma According to Mesenchymal and Adrenergic Signatures. Cancer Res Commun. 2024 08 01; 4(8):2255-2266.

PMID: 39099200

Artificial intelligence-based morphologic classification and molecular characterization of neuroblastic tumors from digital histopathology.

Applebaum M, Ramesh S, Dyer E, Pomaville M, Doytcheva K, Dolezal J, Kochanny S, Terhaar R, Mehrhoff C, Patel K, Brewer J, Kusswurm B, Naranjo A, Shimada H, Sokol E, Cohn S, George R, Pearson A

Artificial intelligence-based morphologic classification and molecular characterization of neuroblastic tumors from digital histopathology. Res Sq. 2024 Jun 04.

PMID: 38883758

Small-molecule inhibition of the METTL3/METTL14 complex suppresses neuroblastoma tumor growth and promotes differentiation.

Pomaville M, Chennakesavalu M, Wang P, Jiang Z, Sun HL, Ren P, Borchert R, Gupta V, Ye C, Ge R, Zhu Z, Brodnik M, Zhong Y, Moore K, Salwen H, George RE, Krajewska M, Chlenski A, Applebaum MA, He C, Cohn SL

Small-molecule inhibition of the METTL3/METTL14 complex suppresses neuroblastoma tumor growth and promotes differentiation. Cell Rep. 2024 05 28; 43(5):114165.

PMID: 38691450

5-Hydroxymethylcytosine Profiling of Cell-Free DNA Identifies Bivalent Genes That Are Prognostic of Survival in High-Risk Neuroblastoma.

Chennakesavalu M, Moore K, Chaves G, Veeravalli S, TerHaar R, Wu T, Lyu R, Chlenski A, He C, Piunti A, Applebaum MA

5-Hydroxymethylcytosine Profiling of Cell-Free DNA Identifies Bivalent Genes That Are Prognostic of Survival in High-Risk Neuroblastoma. JCO Precis Oncol. 2024 Jan; 8:e2300297.

PMID: 38295320

Adrenergic and mesenchymal signatures are identifiable in cell-free DNA and correlate with metastatic disease burden in children with neuroblastoma.

Vayani OR, Kaufman ME, Moore K, Chennakesavalu M, TerHaar R, Chaves G, Chlenski A, He C, Cohn SL, Applebaum MA

Adrenergic and mesenchymal signatures are identifiable in cell-free DNA and correlate with metastatic disease burden in children with neuroblastoma. Pediatr Blood Cancer. 2024 Jan; 71(1):e30735.

PMID: 37859597

Adrenergic and mesenchymal signatures are identifiable in cell-free DNA and correlate with metastatic disease burden in children with neuroblastoma.

Vayani OR, Kaufman ME, Moore K, Chennakesavalu M, TerHaar R, Chaves G, Chlenski A, He C, Cohn SL, Applebaum MA

Adrenergic and mesenchymal signatures are identifiable in cell-free DNA and correlate with metastatic disease burden in children with neuroblastoma. bioRxiv. 2023 Sep 01.

PMID: 37693610

Persistence of Racial and Ethnic Disparities in Risk and Survival for Patients with Neuroblastoma over Two Decades.

Chennakesavalu M, Pudela C, Applebaum MA, Lee SM, Che Y, Naranjo A, Park JR, Volchenboum SL, Henderson TO, Cohn SL, Desai AV

Persistence of Racial and Ethnic Disparities in Risk and Survival for Patients with Neuroblastoma over Two Decades. EJC Paediatr Oncol. 2023 Dec; 2.

PMID: 38213818

T-cell inflammation is prognostic of survival in patients with high-risk neuroblastoma enriched for an adrenergic signature.

Kaufman ME, Vayani OR, Moore K, Chlenski A, Wu T, Chavez G, Lee SM, Desai AV, He C, Cohn SL, Applebaum MA

T-cell inflammation is prognostic of survival in patients with high-risk neuroblastoma enriched for an adrenergic signature. bioRxiv. 2023 Jun 28.

PMID: 37425883